Sunday, October 20

Tag: Diabetes Drugs

Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Bln
4Dec By adminNo Comments
World

Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Bln

Roche aims to buy Carmot Therapeutics, a California-based pharmaceutical firm developing drugs to treat obesity and diabetes.The Swiss pharmaceutical company said it has entered an agreement to acquire the private company for $2.7 billion with additional payments of up to $400 million based on drug-development milestones.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France
24Nov By adminNo Comments
World

Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France

Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for its blockbuster obesity and diabetes treatments.The Danish company, which makes the Wegovy obesity drug and diabetes drug Ozempic, said Thursday that the expansion of its facility in Chartres, southwest of Paris, will more than double the size of the site and is expected to create more than 500 new jobs. Construction, which has already started and will employ up to 2,000 external workers, is set to complete between 2026 and 2028, it said.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
8Nov By adminNo Comments
World

Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.

Updated Nov. 8, 2023 1:01 pm ETU.S. drug regulators have approved expanding the use of Eli Lilly’s diabetes drug Mounjaro to include the treatment of obesity.The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk—that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Obesity Drug Demand Outstrips Supply
3Nov By adminNo Comments
Money

Obesity Drug Demand Outstrips Supply

Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
The ‘Ozempic Effect’ on Wall Street Has Gone Overboard
1Nov By adminNo Comments
World

The ‘Ozempic Effect’ on Wall Street Has Gone Overboard

Updated Nov. 1, 2023 4:39 pm ETAmerica leads developed nations when it comes to obesity. Those paying close attention to the stock market and recent corporate earnings calls might be forgiven for thinking the problem has been solved.Call it the Ozempic effect. A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led to fanciful assumptions on Wall Street that spell doom for companies that have profited from America’s obesity problem. It has also led to speculation that gigantic opportunities await those that would benefit from the aggregate weight loss.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
26Oct By adminNo Comments
World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.2128 GMT – Molina Healthcare keeps its outlook for the year unchanged after posting profit and revenue growth in 3Q. The company’s quarterly results were largely consistent with management expectations, “in addition to considerations of seasonality and conservatism,” Molina Healthcare says. The company’s revenue beat analysts expectations, but earnings per share came below forecasts in the period.Shares rise 0.5% after hours. (sabela.ojea@wsj.com; @sabelaojeaguix)Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Novo Nordiskfound bacteria in batches of the main ingredient for a diabetes pill that is a cousin to popular diabetes and weight-loss drugs and was made at a North Carolina plant earlier this year, according to a federal inspection report reviewed by The Wall Street Journal.
22Sep By adminNo Comments
World

Novo Nordiskfound bacteria in batches of the main ingredient for a diabetes pill that is a cousin to popular diabetes and weight-loss drugs and was made at a North Carolina plant earlier this year, according to a federal inspection report reviewed by The Wall Street Journal.

Novo Nordisk found bacteria in batches of the main ingredient for a diabetes pill that is a cousin to popular diabetes and weight-loss drugs and was made at a North Carolina plant earlier this year, according to a federal inspection report reviewed by The Wall Street Journal.
Read More